Back to Search Start Over

Is antithrombin treatment of disseminated intravascular coagulation a quixotic goal?

Authors :
Anthony F. Suffredini
Nitin Seam
Source :
Critical Care. 18
Publication Year :
2014
Publisher :
Springer Science and Business Media LLC, 2014.

Abstract

The development of disseminated intravascular coagulation (DIC) is associated with increased sepsis mortality. Antithrombin (AT) is one of several anticoagulants that have been studied in randomized trials of sepsis without benefit. In a recent study, Iba and colleagues reviewed data from patients who were treated for sepsis-related DIC with two lower doses of AT concentrate than studied in prior trials. Patients received 1,500 IU/day (n = 259) or 3,000 IU/day (n = 48) of AT for 3 days. All patients had baseline antithrombin activity

Details

ISSN :
13648535
Volume :
18
Database :
OpenAIRE
Journal :
Critical Care
Accession number :
edsair.doi.dedup.....f7920dbe7d0b916a8b4b12da840ab594
Full Text :
https://doi.org/10.1186/s13054-014-0639-1